Protocol of the TREASURE study: Thoracic RadiothErapy with Atezolizumab in Small cell lUng canceR Extensive disease – a randomized, open-label, multicenter phase II trial

被引：0

作者：

Farastuk Bozorgmehr

Petros Christopoulos

Inn Chung

Jelena Cvetkovic

Manuel Feißt

Johannes Krisam

Marc A. Schneider

Claus Peter Heußel

Michael Kreuter

Daniel W. Müller

Michael Thomas

Stefan Rieken

机构：

[1] Thoraxklinik at University Hospital of Heidelberg,Department of Thoracic Oncology

[2] Member of the German Center for Lung Research DZL,Translational Lung Research Center Heidelberg TLRCH

[3] Institute of Medical Biometry,University Hospital of Heidelberg

[4] Translational Research Unit (STF),Thoraxklinik at University Hospital of Heidelberg

[5] Diagnostic and Interventional Radiology with Nuclear Medicine,Thoraxklinik at University Hospital of Heidelberg

[6] Pneumology and Respiratory Care Medicine,Thoraxklinik at University Hospital of Heidelberg, Center for Interstitial and Rare Lung Diseases

[7] Institute of Clinical Cancer Research IKF GmbH at Northwest Hospital,Department of Radiation Oncology

[8] University Medical Center Göttingen,undefined

来源：

BMC Cancer | / 22卷

关键词：

Extensive disease small cell lung cancer; SCLC; Radioimmuntherapy; Thoracic radiotherapy; Atezolizumab; Anti-PD-L1 monoclonal antibody; First-line therapy;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[1] Protocol of the TREASURE study: Thoracic RadiothErapy with Atezolizumab in Small cell lUng canceR Extensive disease - a randomized, open-label, multicenter phase II trial
Bozorgmehr, Farastuk
Christopoulos, Petros
Chung, Inn
Cvetkovic, Jelena
Feisst, Manuel
Krisam, Johannes
Schneider, Marc A.
Heussel, Claus Peter
Kreuter, Michael
Mueller, Daniel W.
Thomas, Michael
Rieken, Stefan
BMC CANCER, 2022, 22 (01)
[2] Thoracic Radiotherapy in Extensive Disease Small Cell Lung Cancer: Multicenter Prospective Observational TRENDS Study
Cozzi, Salvatore
Bruni, Alessio
Ruggieri, Maria Paola
Borghetti, Paolo
Scotti, Vieri
Franceschini, Davide
Fiore, Michele
Taraborrelli, Maria
Salvi, Fabrizio
Galaverni, Marco
Savoldi, Luisa
Braglia, Luca
Botti, Andrea
Ghersi, Sebastiano Finocchi
Niccolo, Giaj-Levra
Lohr, Frank
Iotti, Cinzia
Ciammella, Patrizia
CANCERS, 2023, 15 (02)
[3] A phase II, open-label, single arm, trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale
Andrini, Elisa
Lamberti, Giuseppe
Mazzoni, Francesca
Riccardi, Ferdinando
Bonetti, Andrea
Follador, Alessandro
Artioli, Fabrizio
Genova, Carlo
Barbieri, Fausto
Frassoldati, Antonio
Brighenti, Matteo
Colantonio, Ida
Pasello, Giulia
Ficorella, Corrado
Cinieri, Saverio
Tiseo, Marcello
Gelsomino, Francesco
Tognetto, Michele
Rihawi, Karim
Ardizzoni, Andrea
FUTURE ONCOLOGY, 2022, 18 (07) : 771 - 779
[4] Evaluating atezolizumab in patients with urinary tract squamous cell carcinoma (AURORA): study protocol for a single arm, open-label, multicentre, phase II clinical trial
Simon Crabb
Robin Wickens
Sarah Jane-Bibby
Denise Dunkley
Megan Lawrence
Allen Knight
Robert Jones
Alison Birtle
Robert Huddart
Mark Linch
Jonathan Martin
Adam Coleman
Konstantinos Boukas
Hannah Markham
Gareth Griffiths
BMC Cancer, 23
[5] Evaluating atezolizumab in patients with urinary tract squamous cell carcinoma (AURORA): study protocol for a single arm, open-label, multicentre, phase II clinical trial
Crabb, Simon
Wickens, Robin
Jane-Bibby, Sarah
Dunkley, Denise
Lawrence, Megan
Knight, Allen
Jones, Robert
Birtle, Alison
Huddart, Robert
Linch, Mark
Martin, Jonathan
Coleman, Adam
Boukas, Konstantinos
Markham, Hannah
Griffiths, Gareth
BMC CANCER, 2023, 23 (01)
[6] Safety and efficacy of cobimetinib plus atezolizumab in patients with solid tumors: a phase II, open-label, multicenter, multicohort study
Sherman, E.
Lee, J. L.
Debruyne, P. R.
Keam, B.
Shin, S. J.
Gramza, A.
Caro, I.
Amin, R.
Shah, K.
Yan, Y.
Huddart, R.
Powles, T.
ESMO OPEN, 2023, 8 (02)
[7] Radiotherapy(R) Integration(I) Strategy for Small(S)-Cell Lung Cancer in Extensive(E) Stage (RISE) with up to 10 metastases- a study protocol of a randomized phase II trial
Kuncman, Lukasz
Fijuth, Jacek
Tworek, Damian
Sierko, Ewa
Cisek, Pawel
Maslowski, Michal
Lisik-Habib, Maja
Orzechowska, Magdalena
Galwas-Kliber, Katarzyna
Antczak, Adam
Chmielewska, Izabela
Ziolkowska, Barbara
Kurczewska-Michalak, Marta
Kuznicki, Wojciech
Jedrzejczak, Nina
Ranoszek, Kinga
Bilski, Mateusz
BMC CANCER, 2025, 25 (01)
[8] A phase II open-label multicenter study of gefitinib in combination with irradiation followed by chemotherapy in patients with inoperable stage III non-small cell lung cancer
Levy, Antonin
Bardet, Etienne
Lacas, Benjamin
Pignon, Jean-Pierre
Adam, Julien
Lacroix, Ludovic
Artignan, Xavier
Verrelle, Pierre
Le Pechoux, Cecile
ONCOTARGET, 2017, 8 (09) : 15924 - 15933
[9] Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study
Simonelli, M.
Garralda, E.
Eskens, F.
Gil-Martin, M.
Yen, C-J
Obermannova, R.
Chao, Y.
Lonardi, S.
Melichar, B.
Moreno, V
Yu, M-L
Bongiovanni, A.
Calvo, E.
Rottey, S.
Machiels, J-P
Gonzalez-Martin, A.
Paz-Ares, L.
Chang, C-L
Mason, W.
Lin, C-C
Reardon, D. A.
Vieito, M.
Santoro, A.
Meng, R.
Abbadessa, G.
Menas, F.
Lee, H.
Liu, Q.
Combeau, C.
Ternes, N.
Ziti-Ljajic, S.
Massard, C.
ESMO OPEN, 2022, 7 (05)
[10] Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer: An open-label phase II trial (VinMetAtezo)
Vergnenegre, Alain
Monnet, Isabelle
Ricordel, Charles
Bizieux, Acya
Curcio, Hubert
Bernardi, Marie
Corre, Romain
Guisier, Florian
Hominal, Stephane
Le Garff, Gwenaelle
Bylicki, Olivier
Locher, Chrystele
Geier, Margaux
Chouaid, Christos
Robinet, Gilles
LUNG CANCER, 2023, 178 : 191 - 197

← 1 2 3 4 5 →